Otros idiomas BioCorRx Inc.

Acciones

BICX

US09073C2052

Diferido OTC Markets Otros sitios de cotización 19:15:42 06/05/2024			Varia. Cinco días.	Varia. 1 de enero.
0,78 ^USD	+4,00 %		+4,00 %	0,00 %

03/04	BioCorRx Inc. Anuncia la Dimisión de la Junta Directiva	CI
01/04	BioCorRx Inc. informa de los resultados de las ganancias para el año completo finalizado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

BioCorRx Inc. Announces Board Resignations	03/04
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia	03/04
BioCorRx Reports Business Update for 2023	02/04
BioCorRx Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD	28/02
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors	08/02
BioCorRx Pharmaceuticals Inc. Appoints Kate Devarney to the Board of Directors	08/02
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President	09/01
BioCorRx Inc. Announces President Changes	05/01
BioCorRx : Material Agreement - Form 8-K	15/12
BioCorRx Inc. announced that it has received $0.2 million in funding	08/12
BioCorRx Reports Business Update for the Third Quarter of 2023	14/11
BioCorRx Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
BioCorRx Inc. announced that it has received $0.2 million in funding	10/11
Biocorrx Inc. Announces Management Changes	02/11
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23
BioCorRx Inc. Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder	15/08/23
BioCorRx Reports Business Update for the Second Quarter of 2023	14/08/23
BioCorRx Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder	18/07/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas BioCorRx Inc.

Acciones

BICX

US09073C2052

Otros idiomas

Filtros